Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies

Table 1 Baseline characteristics of the patients n (%)

Variables	Total (n = 50)
Age (yr)1	46.5 (22-74)
Male	37 (74)
HBeAg-positive	47 (94)
Cirrhosis	12 (24)
Antiviral history before ETV (naïve/clevudine/LMV)	2/2/46 (4/4/92)
Duration of ETV (mo)1	24 (13-58)
Serum ALT (IU/L)1	31 (5-1704)
Serum total bilirubin level (mg/dL)1	0.84 (0.28-4.30)
Serum albumin level (g/dL)1	4.2 (3.6-5.1)
INR1	1.01 (0.87-1.30)
Serum HBV DNA level (log10 IU/mL)1	5.53 (2.81-7.63)
Duration of ADV combination therapy (mo)1	27 (12-45)
Site of ETV-resistant mutations added on rtM204V/I
rt184	19 (38)
rt202	22 (44)
rt173	1 (2)
rt169 + rt184	1 (2)
rt184 + rt202	6 (12)
rt184 + rt250	1 (2)
Patients with elevated ALT level above ULN	18 (36)
Rescue therapy regimens [(ADV + LMV)/(ADV + ETV)]	27/23 (54/46)

¹Data are expressed as median (range). ADV: Adefovir; ALT: Alanine aminotransferase; ETV: Entecavir; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; INR: International normalized ratio; LMV: Lamivudine; ULN: Upper limit of normal.